Omega Therapeutics, Inc. Contracts & Agreements
41 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (3)
- Human Resources (12)
- Intellectual Property (4)
- Real Estate (3)
- Uncategorized (9)
- Fifth Amendment to Loan and Security Agreement, dated September 22, 2023 (Filed With SEC on September 22, 2023)
- Open Market Sale Agreement, dated as of August 3, 2023, between Omega Therapeutics, Inc. and Jefferies LLC (Filed With SEC on August 3, 2023)
- First Amendment to Lease between Omega Therapeutics, Inc. and ARE-MA Region No. 94, LLC, dated May 3, 2023 (Filed With SEC on August 3, 2023)
- Shared Space Arrangement, dated as of July 12, 2023, by and between Omega Therapeutics, Inc. and Flagship Labs 89, Inc (Filed With SEC on July 13, 2023)
- Shared Space Arrangement, dated as of July 11, 2023, by and between Omega Therapeutics, Inc. and Apriori Bio, Inc (Filed With SEC on July 13, 2023)
- Shared Space Arrangement, dated as of July 12, 2023, by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc (Filed With SEC on July 13, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on February 23, 2023)
- Employment Agreement by and between Kevin McManus and the Registrant, dated February 3, 2022 (Filed With SEC on May 4, 2022)
- Employment Agreement by and between Ling Zeng and the Registrant, dated March 18, 2022 (Filed With SEC on May 4, 2022)
- Employment Agreement by and between Joshua Reed and the Registrant, dated April 28, 2022 (Filed With SEC on May 4, 2022)
- Amendment to Shared Space Agreement between Omega Therapeutics, Inc. and Senda Biosciences, Inc., dated January 31, 2022 (Filed With SEC on March 10, 2022)
- Lease Agreement between Omega Therapeutics, Inc. and ARE-MA Region No, 94, LLC (Filed With SEC on March 10, 2022)
- Amendment to Consulting Agreement by and between Richard A. Young and the Registrant, dated October 29, 2021 (Filed With SEC on March 10, 2022)
- Consulting Agreement by and between Richard A. Young and the Registrant, dated November 7, 2016 (Filed With SEC on March 10, 2022)
- Employment Agreement by and between Yan Moore and the Registrant, dated December 12, 2021 (Filed With SEC on March 10, 2022)
- Description of Capital Stock (Filed With SEC on March 10, 2022)
- Fourth Amendment to Loan and Security Agreement, dated December 20, 2021 (Filed With SEC on December 21, 2021)
- Development and Option Agreement between Acuitas Therapeutics, Inc. and the Registrant, dated October 5, 2020, as amended (Filed With SEC on July 26, 2021)
- Employment Agreement between Roger Sawhney and the Registrant, dated July 24, 2021 (Filed With SEC on July 26, 2021)
- Employment Agreement between Thomas McCauley and the Registrant, dated July 24, 2021 (Filed With SEC on July 26, 2021)
- Employment Agreement between Mahesh Karande and the Registrant, dated July 25, 2021 (Filed With SEC on July 26, 2021)
- Loan and Security Agreement between Pacific Western Bank (n/k/a PacWest Bancorp) and the Registrant, dated March 9, 2018, as amended on September 30, 2019, January 22, 2020 and... (Filed With SEC on July 26, 2021)
- Lease Agreement between BMR-325 Vassar Street LLC and the Registrant, dated November 30, 2017 (Filed With SEC on July 26, 2021)
- Shared Space Arrangement between Kintai Therapeutics, Inc. (n/k/a Senda Biosciences, Inc.) and the Registrant, dated July 13, 2020 (Filed With SEC on July 26, 2021)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on July 26, 2021)
- Non-Employee Director Compensation Program (Filed With SEC on July 26, 2021)
- 2021 Employee Stock Purchase Plan (Filed With SEC on July 26, 2021)
- 2021 Incentive Award Plan and form of agreements thereunder (Filed With SEC on July 26, 2021)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on July 26, 2021)
- Form of Underwriting Agreement (Filed With SEC on July 26, 2021)
- Amended and Restated Warrant to Purchase Stock issued to PacWest Bancorp, dated September 30, 2019, to purchase Series A preferred stock (Filed With SEC on July 9, 2021)
- Amended and Restated Investors Rights Agreement, dated March 4, 2021 (Filed With SEC on July 9, 2021)
- 2017 Equity Incentive Plan, as amended, and form of option agreements thereunder (Filed With SEC on July 9, 2021)
- Offer Letter between Mahesh Karande and the Registrant, dated March 2, 2019 (Filed With SEC on July 9, 2021)
- Offer Letter between Tom McCauley and the Registrant, dated July 10, 2019 (Filed With SEC on July 9, 2021)
- Offer Letter between Roger Sawhney and the Registrant, dated March 25, 2020 (Filed With SEC on July 9, 2021)
- License Agreement between Flagship Pioneering Innovations V, Inc. and the Registrant, dated March 12, 2019 (Filed With SEC on July 9, 2021)
- Exclusive License Agreement between the Whitehead Institute for Biomedical Research and the Registrant, dated May 22, 2019 (Filed With SEC on July 9, 2021)
- Co-Exclusive License Agreement between the Whitehead Institute for Biomedical Research and the Registrant, dated May 22, 2019 (Filed With SEC on July 9, 2021)
- Development and Option Agreement between Acuitas Therapeutics, Inc. and the Registrant, dated October 5, 2020, as amended (Filed With SEC on July 9, 2021)
- Non-Exclusive License Agreement between Acuitas Therapeutics, Inc. and the Registrant, dated March 22, 2021 (Filed With SEC on July 9, 2021)